GLP-1R modulating compounds

Patent metadata

Field	Value
Publication number	US-12473271-B2
Application number	US-202318502972-A
Country	US
Kind code	B2
Filing date	Nov 6, 2023
Priority date	Nov 20, 2020
Publication date	Nov 18, 2025
Grant date	Nov 18, 2025

Abstract

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

First claim

What is claimed is:

1 . A method of treating a GLP-1R mediated disease or condition comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure:

2 . The method of claim 1 , wherein the disease or condition comprises a liver disease.

3 . The method of claim 2 , wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Choleangitis (PSC).

4 . The method of claim 3 , wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

5 . The method of claim 3 , wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

6 . The method of claim 1 , wherein the disease or condition comprises a metabolic disease.

7 . The method of claim 1 , wherein the disease or condition comprises type 1 diabetes, type 2 diabetes, pre-diabetes, idiopathic type 1 diabetes, latent autoimmune diabetes, maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

8 . The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof is administered in combination with an additional therapeutic agent.

9 . The method of claim 8 , wherein the additional therapeutic agent comprises an anti-obesity agent selected from peptide YY, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor, a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist, apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor, an opioid receptor antagonist, a combination of a norepinephrine/dopamine reuptake inhibitor and an opioid receptor antagonist, sibutramine, a cholecystokinin agonist, amylin, leptin, a serotonergic agent, a methionine aminopeptidase 2 (MetAP2) inhibitor, phendimetrazine, diethylpropion, benzphetamine, an SGLT2 inhibitor, an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.

Assignees

• Gilead Sciences Inc

Inventors

• Brizgys Gediminas J
• Cassidy James S
• Chou Chienhung
• Cottell Jeromy J
• Hung Chao-I
• Kolahdouzan Kavoos
• Taylor James G
• Wright Nathan E
• Yang Zheng-Yu

Classifications

• C07D405/14

  containing three or more hetero rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title